Recently, studies have shown that anti-miR-33 treatments, especially anti-miR-33b, ameliorated liver dysfunction and improved the serum and liver lipid profile in Gubra amylin NASH (GAN) diet-induced mice with miR-33b knockin in the intron of SREBP1. 413. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatohepatitis.